At 1 year, BCVA showed no significant difference compared to baseline; however, it showed a trend toward improvement, with a significant improvement over baseline at 6 months and at the final observation.
← all excerpts
Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema.
1
—
—